Palonossetrom Pharmamatch (Palonosetron)

Palonosetron, the active ingredient in Palonossetrom Pharmamatch, is a 5-HT3 receptor antagonist presented as a strength/form for intravenous use. It treats and prevents chemotherapy‑induced nausea and vomiting in adult cancer patients. GNH USA supplies Palonossetrom Pharmamatch as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

GNH USA supplies Palonossetrom Pharmamatch as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Palonosetron is a selective 5‑HT3 receptor antagonist used in the management of nausea and vomiting associated with chemotherapy and surgery.

- Chemotherapy‑induced nausea and vomiting (CINV): provides prophylaxis and acute control of emesis. - Post‑operative nausea and vomiting (PONV): reduces incidence of nausea after general anesthesia. - Radiotherapy‑induced nausea: helps control nausea associated with certain radiation treatments. - Anticipatory nausea: used in patients with a history of severe CINV to prevent anticipatory episodes. - Adjunct therapy in highly emetogenic regimens: enhances overall anti‑emetic coverage when combined with other agents.

Palonosetron is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Constipation: reduced bowel movements. - Fatigue: feeling of tiredness. - Dizziness: transient light‑headedness. - Injection site erythema: mild redness at the administration site.

Serious or Rare Side Effects: - Hypersensitivity reactions: rash, itching, swelling, or anaphylaxis. - QT interval prolongation: potential cardiac rhythm changes. - Severe constipation or intestinal obstruction. - Serotonin syndrome: rare when combined with other serotonergic drugs. - Neurotoxicity: uncommon neurological symptoms such as tremor.

Palonosetron should be used with consideration of patient‑specific factors and safety guidelines.

- Pregnancy: avoid unless clearly needed; limited data available. - Breastfeeding: monitor infant; drug may be present in milk. - Cardiac risk: assess QT interval in patients with known cardiac disease. - Drug interactions: review concomitant serotonergic agents. - Renal/hepatic impairment: adjust if severe organ dysfunction is present. - Store at below 25°C: keep in original packaging, protect from moisture and light.

Palonosetron may interact with other medications that affect serotonin pathways or cardiac conduction.

Major Interactions (Avoid): - Other 5‑HT3 antagonists: additive anti‑emetic effect may increase risk of QT prolongation. - Drugs that prolong QT interval: combined use can exacerbate cardiac rhythm disturbances.

Moderate Interactions (Monitor Closely): - Serotonergic agents (e.g., SSRIs, SNRIs, tramadol): monitor for serotonin syndrome. - CYP3A4 inhibitors/inducers: may alter palonosetron plasma levels. - Anticholinergic drugs: may enhance constipation risk. - Diuretics: monitor electrolyte balance, especially potassium. - Anticoagulants: observe for any unexpected bleeding patterns.